Identification Of Possible Biomarkers In Non-Small Cell Lung Cancer: Identification Of Possible New Biomarkers In Non-small Cell Lung Cancer Using Microarray Analysis Of Raw Patient Data

Research is a high concept; it brings to test our patience, vigor and dedication. Every result arrived at a beginning for higher achievements. Our project in the same interest is just a drop in the ocean. At the same time Cancer biomarker−based diagnostics have applications for establishing disease predisposition, early detection, cancer staging, therapy selection, identifying whether or not a cancer is metastatic, therapy monitoring, assessing prognosis, and advances in the adjuvant setting. New laboratory methods, improvements in the tools available to scientists, and an overriding need to improve cancer therapies are driving current efforts to map cancer-related changes in the body. These changes encompass predisposition or risk factors associated with cancer and subsequent developments of the disease. The need to identify and understand cancer biomarkers is being driven by a number of factors. These include requirements to improve screening and early detection, to provide better guidance on therapy, and to avoid therapy resistance attributes, for understanding cancer staging, response to treatment, and prognosis.